According to Bernstein Research, prices of ingredients needed to make some common medicines such as statins have risen 40% or more for some drugmakers amid the COVID-19 outbreak, reported The Wall Street Journal.
The Financial Times reported last month that Indian drugmakers were struggling to source a basic raw material needed for paracetamol, also known as acetaminophen, an active ingredient in Tylenol that was among the drugs restricted for export this week by regulators in India.
However, the news source said large global pharmaceutical makers tend to hold substantial inventory, so if disruptions in China ease over the next two months, serious shortages may well be averted.
Industry experts interviewed by Bernstein Research in late February said inventories were mostly sufficient for several months, while many of the experts said substantial shortages were unlikely before the late second or early third quarter.
To read more NewsPoints articles, click here.